Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Canavan Disease

Neurological & Neuromuscular

Canavan Disease Clinical Trials and Treatments

Also called Canavan-Van Bogaert-Bertrand disease, aspartoacylase deficiency, spongy degeneration

Canavan disease (also called Canavan-Van Bogaert-Bertrand disease) is a rare autosomal recessive leukodystrophy caused by mutations in the ASPA gene encoding aspartoacylase, a key enzyme in brain metabolism. This enzyme normally catalyzes hydrolysis of N-acetylaspartate (NAA) to aspartate and acetate, both critical metabolites in the central nervous system. Loss of enzymatic activity causes massive accumulation of NAA in the brain, with characteristic spongy degeneration of white matter defined by intramyelinic edema and vacuolation.

In plain words, Canavan disease is an inherited condition in which a missing helper protein lets a natural chemical build up in the brain. The buildup damages the brain's white matter, which slows a baby's development and causes skills to fade over time.

Get an email when new Canavan Disease trials open or the FDA decides. Get alerts

Canavan Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Canavan Disease yet.

Canavan Disease has no FDA-approved medicines, 2 open or active clinical trials (2 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Canavan Disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Canavan Disease

Patients present in infancy with hypotonia (decreased muscle tone) and developmental delay, typically manifesting by 3-6 months of age with failure to meet developmental milestones. Progressive spasticity develops during the second year of life affecting lower more than upper limbs. Seizures occur in most patients. Visual and hearing loss develop as disease progresses.

Keep reading about Canavan Disease

Most patients become vegetative (profoundly disabled with minimal awareness) by late childhood. MRI characteristically shows white matter changes with a spongy appearance. The severe infantile form presents by 6 months with rapid progression, while rare juvenile variants present later with slower progression but still lead to significant neurological disability.

What are the symptoms of Canavan Disease?

These are common symptoms of Canavan Disease, and how strong they are varies from person to person.

  • Developmental delay and hypotonia in infancy
  • Loss of developmental milestones
  • Spasticity developing in second year of life
  • Seizures
  • Visual and hearing loss
  • Progressive quadriplegia

Who gets Canavan Disease?

Canavan disease typically manifests by age 3-6 months with developmental delay and hypotonia. The condition affects males and females equally. It shows notably higher prevalence in the Ashkenazi Jewish population (approximately 1 in 6,400 to 1 in 13,500) compared to general population (approximately 1 in 100,000), though cases occur across all ethnicities.

Autosomal recessive inheritance means both parents must carry mutations, and approximately 25% of offspring in carrier couples will be affected.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Canavan Disease medicines are in trials?

Investigational medicines Trial Friend tracks for Canavan Disease, with trial results, safety findings and where each one stands.

How to get help paying for Canavan Disease treatment

Charity funds and drugmaker programs for Canavan Disease, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · United Leukodystrophy Foundation
    Hultman Memorial Fund fund
    Open

    Pays for: Expenses directly related to the affected family member, based on demonstrated hardship (per 12 months), up to $500 per year.

    The foundation says: “Applications are reviewed on a rolling basis as funding is available.”
Status as each foundation showed it on November 16, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Canavan Disease

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Canavan Disease resources

Reputable organizations and medical references for learning more about Canavan Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Canavan Disease

Use this Canavan Disease clinical trial finder to see the 2 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

2 active trials worldwide
Filter:
Sort:
RecruitingPatient registry covering many conditionsRecently updatedNCT03047369

The Myelin Disorders Biorepository Project

Sponsor: Children's Hospital of Philadelphia · Biogen + 5 more

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, havin...

Ages not specified
Started Dec 2016Updated 6 days agoEst. Dec 2030 (~4 years)
RecruitingTreatment trialPhase 1/2No updates in a whileNCT04998396

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Intervention: AAV9 BBP-812

Sponsor: Aspa Therapeutics

The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.

Ages up to 30 Months3 locations
Started Sep 2021Updated 7 months agoEst. Oct 2026
Find Canavan Disease trials near you, ranked by distance →
Active trial locations24 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+16 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Canavan Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Canavan Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Canavan Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Canavan Disease patients, caregivers and advocacy groups talk.

Companies developing Canavan Disease treatments

Drugmakers that list Canavan Disease in their rare disease portfolio, 1 in all.

Questions people ask about Canavan Disease